30 Day FR Notice

Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
approval of the information collection
described in Section A. The Federal
Register notice that solicited public
comment on the information collection
for a period of 60 days was published
on June 1, 2020 at 85 FR 33189.
A. Overview of Information Collection
Title of Information Collection:
Mortgage Record Change.
OMB Approval Number: 2502–0422.
Type of Request: Extension.
Form Number: 92080 (FHA
Connection).
Description of the need for the
information and proposed use:
Servicing of insured mortgages must be
performed by a mortgagee that is
approved by HUD to service insured
mortgages. The Mortgage Record Change
information is used by FHA-approved
mortgagees to comply with HUD
requirements for reporting the sale of a
mortgage between investors and/or the
transfer of the mortgage servicing
responsibility, as appropriate.
Respondents (i.e. affected public):
Not-for-profit institutions.
Estimated Number of Respondents:
10,000.
Estimated Number of Responses:
3,500,000.
Frequency of Response: On occasion
at sale or transfer.
Average Hours per Response: .1.
Total Estimated Burdens: 350,000.

jbell on DSKJLSW7X2PROD with NOTICES

B. Solicitation of Public Comment
This notice is soliciting comments
from members of the public and affected
parties concerning the collection of
information described in Section A on
the following:
(1) Whether the proposed collection
of information is necessary for the
proper performance of the functions of
the agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information;
(3) Ways to enhance the quality,
utility, and clarity of the information to
be collected; and
(4) Ways to minimize the burden of
the collection of information on those
who are to respond; including through
the use of appropriate automated
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses.
(5) ways to minimize the burden of
the collection of information on those
who are to respond, including the use
of automated collection techniques or
other forms of information technology.
HUD encourages interested parties to
submit comments in response to these
questions.

VerDate Sep<11>2014

18:31 Jan 22, 2021

Jkt 253001

C. Authority
Section 2 of the Paperwork Reduction
Act of 1995, 44 U.S.C. 3507.
Colette Pollard,
Department Reports Management Officer,
Office of the Chief Information Officer.
[FR Doc. 2021–01520 Filed 1–22–21; 8:45 am]
BILLING CODE 4210–67–P

DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–7034–N–05; OMB Control
No.: 2502–0524]

30-Day Notice of Proposed Information
Collection: Home Equity Conversion
Mortgage (HECM) Insurance
Application for the Origination of
Reverse Mortgages and Related
Documents
Office of the Chief Information
Officer, HUD.
ACTION: Notice.
AGENCY:

HUD has submitted the
proposed information collection
requirement described below to the
Office of Management and Budget
(OMB) for review, in accordance with
the Paperwork Reduction Act. The
purpose of this notice is to allow for an
additional 30 days of public comment.
DATES: Comments Due Date: February
24, 2021.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
Start Printed Page 15501PRAMain. Find
this particular information collection by
selecting ‘‘Currently under 30-day
Review—Open for Public Comments’’ or
by using the search function.
FOR FURTHER INFORMATION CONTACT:
Colette Pollard, Reports Management
Officer, QDAM, Department of Housing
and Urban Development, 451 7th Street
SW, Washington, DC 20410; email
Colette Pollard at Colette.Pollard@
hud.gov or telephone 202–402–3400.
Persons with hearing or speech
impairments may access this number
through TTY by calling the toll-free
Federal Relay Service at (800) 877–8339.
This is not a toll-free number. Copies of
available documents submitted to OMB
may be obtained from Ms. Pollard.
SUPPLEMENTARY INFORMATION: This
notice informs the public that HUD has
submitted to OMB a request for
approval of the information collection
described in Section A. The Federal
SUMMARY:

PO 00000

Frm 00054

Fmt 4703

Sfmt 4703

6915

Register notice that solicited public
comment on the information collection
for a period of 60 days was published
on September 17, 2020 at 85 FR 58068.
A. Overview of Information Collection
Title of Information Collection: Home
Equity Conversion Mortgage (HECM)
Insurance Application for the
Origination of Reverse Mortgages and
Related Documents.
OMB Approval Number: 2502–0524.
Type of Request: Revision of currently
approved collection.
Form Number: HUD–92901, HUD–
92902, HUD–92051, HUD–92561, HUD–
92800.5b, HUD–92900–A, HUD–92300,
HUD–1, HUD–1a, Fannie Mae (FNMA)1009, FNMA–1025, FNMA–1003,
FNMA–1004, FNMA–1004c, FNMA–
1073, HUD–92541, HUD–92544,
NPMA–99A, NPMA–99B
Description of the need for the
information and proposed use: The
Home Equity Conversion Mortgage
(HECM) program is the Federal Housing
Administration’s (FHA) reverse
mortgage program that enables seniors
who have equity in their homes to
withdraw a portion of the accumulated
equity. The intent of the HECM Program
is to ease the financial burden on
elderly homeowners facing increased
health, housing, and subsistence costs at
a time of reduced income. The currently
approved information collection is
necessary to screen mortgage insurance
applications to protect the FHA
insurance fund and the interests of
consumers and potential borrowers.
Specific forms and related documents
are needed to determine the eligibility
of the borrower and proposed mortgage
transaction for FHA’s insurance
endorsement. The model HECM
Adjustable Rate Note has been revised
to align with FHA’s transition from the
London InterBank Offered Rate (LIBOR)
index to the Secured Overnight
Financing Rate (SOFR) index, which
includes, but is not limited to, new
definitions and replacement index
language for future adjustable interest
rate index transition events.
HUD also proposes to strengthen the
HECM for Purchase property eligibility
requirements by requiring inspection
documentation for newly built
properties that will serve as collateral
for HECM financing. Currently, the
HECM for Purchase program requires
mortgagees to submit a Certificate of
Occupancy, or its equivalent, as
evidence that the property is complete
and habitable as a condition of FHA
insurance. In the near future,
mortgagees may be required to complete
and submit the following forms to FHA:
(1) Form HUD–92541, Builder’s

E:\FR\FM\25JAN1.SGM

25JAN1

6916

Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices

Certification of Plans, Specifications,
and Site; (2) Form HUD–92544,
Warranty of Completion of
Construction; (3) Form HUD–NPMA–
99–A, Subterranean Termite Protection
Builder’s Guarantee; and (4) Form
HUD–NPMA–99–B, New Construction
Subterranean Termite Service Record.
These forms are currently required by
FHA for maximum financing for FHA’s
Title II Single Family forward mortgage
programs and will align both the reverse
and forward mortgage programs to
ensure the property meet’s FHA’s
minimum property standards while
ensuring the home is safe, sound, and
secure for the HECM borrower.
Respondents (i.e., affected public):
Business or other for profit.
Estimated Number of Respondents:
2,375.
Estimated Number of Responses:
59,375.
Frequency of Response: Occasionally.
Average Hours per Response: 2.54
hours.
Total Estimated Burdens: 116,398.75.
B. Solicitation of Public Comment

jbell on DSKJLSW7X2PROD with NOTICES

This notice is soliciting comments
from members of the public and affected
parties concerning the collection of
information described in Section A on
the following:
(1) Whether the proposed collection
of information is necessary for the
proper performance of the functions of
the agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information;
(3) Ways to enhance the quality,
utility, and clarity of the information to
be collected; and
(4) Ways to minimize the burden of
the collection of information on those
who are to respond: Including through
the use of appropriate automated
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses.
(5) Ways to minimize the burden of
the collection of information on those
who are to respond, including the use
of automated collection techniques or
other forms of information technology.
HUD encourages interested parties to
submit comments in response to the
proposed changes.
Authority: Section 3507 of the Paperwork
Reduction Act of 1995, 44 U.S.C. Chapter 35.
Colette Pollard,
Department Reports Management Officer,
Office of the Chief Information Officer.
[FR Doc. 2021–01515 Filed 1–22–21; 8:45 am]
BILLING CODE 4210–67–P

VerDate Sep<11>2014

18:31 Jan 22, 2021

Jkt 253001

INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1238]

Certain Plant-Derived Recombinant
Human Serum Albumins (‘‘rHSA’’) and
Products Containing Same; Notice of
Institution of Investigation
International Trade
Commission.
ACTION: Notice.
AGENCY:

Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
December 16, 2020, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Ventria Bioscience Inc. of
Junction City, Kansas. Supplements to
the complaint were filed on December
16, and 22, 2020. The complaint, as
supplemented, alleges violations of
section 337 based upon the importation
into the United States, the sale for
importation, and the sale within the
United States after importation of
certain plant-derived recombinant
human serum albumins (‘‘rHSA’’) and
products containing same by reason of
infringement of certain claims of U.S.
Patent No. 10,618,951 (‘‘the ’951
patent’’); and U.S. Patent No. 8,609,416
(‘‘the ’416 patent’’). The complaint
further alleges that an industry in the
United States exists as required by the
applicable Federal Statute. The
complaint also alleges violations of
section 337 based on the importation
into the United States, or in the sale of,
certain plant-derived recombinant
human serum albumins (‘‘rHSA’’) and
products containing same by reason of
false designation of origin, the threat or
effect of which is to destroy or
substantially injure an industry in the
United States.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
SUMMARY:

PO 00000

Frm 00055

Fmt 4703

Sfmt 4703

the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2020).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
January 14, 2021, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine:
(a) Whether there is a violation of
subsection (a)(1)(B) of section 337 in the
importation into the United States, the
sale for importation, or the sale within
the United States after importation of
certain products identified in paragraph
(2) by reason of infringement of one or
more of claims 1–3 and 11–13 of the
’951 patent and claims 1–3, 5–7, 10, 12,
18–20, and 22–25 of the ’416 patent; and
whether an industry in the United
States exists as required by subsection
(a)(2) of section 337; and
(b) Whether there is a violation of
subsection (a)(1)(A) of section 337 in the
importation into the United States, or in
the sale of, certain products identified
in paragraph (2) by reason of false
designation of origin.
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is: Plant-derived
recombinant human serum albumins
(‘‘rHSA’’) and products containing the
same, such as lyophilized powders and
liquid suspensions primarily containing
rHSA along with naturally-occurring
plant expression by-products, such as
plant heat shock proteins and/or plant
fatty acids, as well as cell culture media
supplements formulated with such
rHSA products.
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is: Ventria
Bioscience Inc., 2718 Industrial Drive,
Junction City, Kansas 66441.

E:\FR\FM\25JAN1.SGM

25JAN1